Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study

To determine the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) on the risk of major cardiocerebrovascular and renal outcomes compared with sulfonylurea (SU) combined with metformin in patients with type 2...

Source: Cardiovascular Diabetology - March 11, 2019 Category: Cardiology Authors: Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim and Nam Hoon Kim Tags: Original investigation Source Type: research